Core Viewpoint - The company expects a decline in revenue and net profit for the first half of 2025, primarily due to market environment changes and product price adjustments [2][3]. Performance Changes - The decline in performance is attributed to changes in the market environment in the second half of 2024 and adjustments in product pricing [3]. - Despite the challenges, innovative products such as Castor® and Minos® continue to show growth in hospital admissions and terminal implant volumes, although pricing and promotional strategy adjustments have impacted sales growth and profits [3]. New Product and R&D Progress - The company has made significant progress in new product development and market expansion, launching the next-generation Cratos® and receiving approval for the Tipspear® kit [5]. - Hector® has entered the special review process for innovative medical devices, marking the ninth product to enter the "green channel" for approval [5]. - The core product Castor® has received the 25th China Patent Gold Award for its patented technology [5]. Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. was established in 2012 and focuses on the research, production, and sales of interventional medical devices for aortic, peripheral vascular, and tumor treatments [6]. - The company has a rich product line in the aortic and peripheral vascular interventional medical device field, including aortic stent systems and intraoperative stent systems [6][7]. - As of March 2025, the company's products are used in over 2,700 hospitals across China and have expanded to over 40 countries and regions [7].